2025 International Workshop on HIV Drug Resistance and Treatment Strategies program
CLICK HERE TO DOWNLOAD A COPY OF THE FULL PROGRAM
PRESENTATIONS
Monday, 1 September 2025
Strengthening healthcare during times of transitions, and potential impact on resistance: South African perspective | Francois Venter
Strengthening healthcare during times of transitions, and potential impact on resistance: Botswana perspective | Ava Avalos
Advances in HIV treatment strategies | Dan Kuritzkes
A French national real-world observatory of people initiating a lenacapavir-based treatment during the post-approval period | Charlotte Charpentier
Tuesday, 2 September 2025
Phenotypic impact of INSTI-associated DRMs / understanding of the mutations | Robert Shafer
Resistance to broadly neutralising antibodies in young children | Natasha Moraka
Resistance and genetic barrier of new antiretroviral compounds | Charlotte Charpentier
Mechanistic Analysis of INSTI Resistance Conferred by NC Mutations | Yuta Hikichi
Emergence of HIV-1 Nucleocapsid Mutations in TLD-Treated Individuals with Unexplained Virological Failure | Nicola Coetzee
Genomic pandemic surveillance | Tulio de Oliveira
Drug resistance and treatment strategies in children and adolescents | Moherndran Archary
Dolutegravir Resistance among Virally Non-Suppressed Adults and Children Remains Low in South Africa | Cheri van der Walt
Wednesday, 3 September 2025
Injectable Lenacapavir for PrEP | Katherine Gill
Prevalence and Dynamics of HIV Drug Resistance During Dolutegravir-Containing Treatment in a Pediatric Population Living with HIV | Ceejay Boyce
HIV-1 Integrase and 3’-Polypurine Tract Mutations in People with HIV Failing Dolutegravir Therapy in Brazil | Jeroen van Kampen
Noncanonical Second-line Protease Inhibitor Resistance Mutations in Non-B HIV-1 Subtypes in Africa | Brianna Lindsay
Investigating Dolutegravir Resistance in the South African Setting by IonTorrent Next-Generation Sequencing | Chijioke Umunnakwe
Thursday, 4 September 2025
Modelling policy options for people with viral non-suppression on tenofovir-lamivudine-dolutegravir: findings from two recent studies | Andrew Phillips
Drug Exposure testing as a tool to predict the presence of resistance | Monica Gandhi
Patterns of HIV-1 Viral Load Suppression and Drug Resistance During the Dolutegravir Transition: A Population-Based Longitudinal Study | Michael Martin
HIV Drug Resistance Among People Living with HIV on Dolutegravir based Antiretroviral Therapy in Four African Countries | Ajay Parikh
Patterns of Dolutegravir Resistance in Africa 2022-2025: the DTG RESIST Study of IeDEA | Tom Loosli
Relevance of DNA resistance profiles (limitations of DNA sequencing) | Francesca Ceccherini-Silberstein
Prevalence of HIV drug resistance in patients with low-level viraemia | Avelin Aghokeng
Follow up after DTG Resistance | Suzanne McCluskey
POSTER ABSTRACTS
Abstract Number; Abstract Title; Initial; Surname
4 Dolutegravir Resistance among Virally Non-Suppressed Adults and Children Remains Low in South Africa | C van der Walt
7 HIV-1 Integrase and 3’-Polypurine Tract Mutations in People with HIV Failing Dolutegravir Therapy in Brazil | J van Kampen
14 Dolutegravir Resistance Detected More Frequently When Co-administered with Zidovudine or Abacavir Compared to Tenofovir | C Boyce
17 Evaluation of Dried Blood Specimens for HIV-1 Drug Resistance Testing Using a Commercial HIV Drug Resistance Assay | O Okafor
18 Trends of Major Dolutegravir Mutations in HIV-1 Virologic Failure in Kampala Uganda, 2021-2023 | J Owori
19 The Clinical Management of Clients with HIV Genotypic Resistance Testing in Five South African Districts | L Gilbert
20 Profile of Antiretroviral Resistance in Children Born to HIV-Positive Mothers on Dolutegravir in Togo from 2021 to 2023 | K Tegueni
21 Low Acquired Dolutegravir Resistance Among PLHIV with Low Level Viremia in Uganda: A National Laboratory Survey Using Remnant Samples during November 2022 – June 2023 | G Namayanja
22 Pre Treatment HIV Drug Resistance Among Individuals Initating ART In Greater Gaborone, Botswana | N Moraka
23 Analysis of Dolutegravir Resistance Patterns from a Private Laboratory, South Africa. | R Mafuyeka
24 KwaZulu-Natal Paediatric Third-line Antiretroviral Therapy Committee Post-Implementation Experiences and HIV Drug Resistance Patterns | A Khan
25 Adolescents with confirmed virological failure stand at risk of acquiring resistance to dolutegravir and need novel treatment options: Findings during the early stage of TLD transition in the CIPHER-ADOLA study | Y Bouba
26 Emerging Acquired Dolutegravir Resistance and Darunavir Associated Mutations Among People Living with HIV-1 on Antiretroviral therapy in West Nile Region in Uganda From 2021-2023 | F Kayinda
27 The Patterns of HIV Drug Resistance in Newly Diagnosed Infants in KwaZulu-Natal Province, South Africa. | T Mosito
28 HIV Viral Load Suppression Amongst the Incarcerated Populations in Cameroon | A Fualefac
29 Pre-treatment Doravirine Drug Resistance in an Antiretroviral (ART) Naïve South African Cohort | J Woods
30 HIV Drug Resistance Profiles Amongst Participants Who Were Virally Non-suppressed in the Sixth South African National HIV Prevalence, Incidence and Behavior Survey (SABSSM VI), 2022 | S Moyo
31 Outcomes After Switch to Protease Inhibitor-based Antiretroviral Therapy Among People with Acquired Dolutegravir Resistance in Lesotho | B Lukau
32 Optimisation of an In-house Multiplex PCR for Antiretroviral Drug Resistance Testing | K van Eck
33 Acquired HIV Drug Resistance to Dolutegravir among Persons Living with HIV in Uganda: Analysis of Uganda National Viral Load Program Remnant Specimens Surveillance data, 2023 | C Watera
34 Frequency of Mutations in the 3′ Polypurine Tract (3′-PPT) of nef in People with Viraemia on Dolutegravir-Based ART Across HIV-1 Subtypes in Africa | J Giandhari
35 Low Frequency Integrase Drug Resistance Mutations in People With Virological Failure on Dolutegravir-based Antiretroviral Therapy | S Naidoo
36 Emergence of Dolutegravir resistance in integrase strand transfer inhibitor-naïve patients in KwaZulu-Natal, South Africa | M Pillay
37 Pretreatment HIV Drug Resistance in Adults in Ukraine in 2023 | M Liulchuk
38 Possible Alternative Mechanism of Resistance to Dolutegravir in ARTIST after 2 Years on Second-Line Antiretroviral Therapy | K Delaney
39 Rapid Drug Resistance Development During Initial Dolutegravir Treatment of an Infant with HIV | T von Mollendorff
40 Treatment Outcomes in Patients who Switched to Dolutegravir Following Failure of a Protease Inhibitor-based ART regimen | M Kakubu
41 HIV Non-Suppression and Antiretroviral Drug Resistance in Angola Based Results from a Nationally Representative Cross-Sectional Survey | B Pocongo
42 Most instances of persistent low-level HIV viremia during ART are not attributable to either low antiretroviral drug levels or emerging drug resistance | A Cabral da Silva
43 Persistent (> 6 year) Detectable Plasma Viral Loads Caused by DNA Contamination from a Massively Clonally-Expanded, Genetically-Defective, Drug-Susceptible Provirus | E Barad
45 HIV Superinfections and Dolutegravir Resistance in South Africa: a Modelling Study | G Wick
46 Trends in Pretreatment Drug-Resistance in Japan, 2020–2023: Increase in M184V Prevalence Among Treatment-Naive Individuals and Association with PrEP Use | T Kikuchi
47 Mutational Pathways of Emergent Dolutegravir Resistance in the DTG RESIST Study | R Schill
48 Selection of mutations in the 3’ polypurine tract of HIV-1 under selective drug pressure with integrase inhibitors | J van Osch
49 Novel Associations between Integrase Mutations and Genotypic DTG Resistance in the DTG RESIST Study | N Han
50 Low Prevalence of Lenacapavir Resistance Among Treatment-Experienced People Living with HIV in South Africa | L Gaelejwe
51 Accurate Detection of Dolutegravir and Protease Inhibitor Resistance Mutations Using the Pan Degenerate Amplification and Adaptation (PANDAA TM) Assay | B Buma
52 Characteristics and Outcome of Children and Adolescents Referred to the Third-Line Antiretroviral Therapy Programme in the Western Cape province, South Africa: an 8-year Review | N O’Connell
53 Estimating the Genetic Barrier for Resistance to Integrase Inhibitors for the Most Frequently Circulating HIV-1 Subtypes | J van Kampen
54 HIV drug resistance among adults with HIV and TB receiving bictegravir- or dolutegravir-based ART, during rifampicin-based TB treatment in South Africa: INSIGHT trial | B Chimukangara
55 Prevalence of Epistatic HIV env and gag Mutations in People with HIV with Persistent Low-level Viremia Using a Dolutegravir-containing Regimen in São Paulo, Brazil. | R Diaz
56 Optimization and Verification of IonTorrent Next-Generation Sequencing Workflow for HIV Drug Resistance Genotypic Testing. | C Seema
57 Virological re-suppression in the presence of major dolutegravir resistance mutations: a case series. | L du Toit
58 Quantitative Detection of Low Levels of Drug Resistance to Nucleoside Reverse Transcriptase Inhibitors by RT-qPCR | D Mims
59 An Enzymatic Assay for Rapid Measurement of Tenofovir Diphosphate with Lateral Flow Readout | M Singh
60 HIV Drug Resistance in Indonesian Persons with HIV and Virologic Failure in the INA-PROACTIVE Study: Distinct Resistance Profiles in Adults and Children | W Wulan
61 Monitoring of HIV Drug Resistance in Cameroon reveals Major Clinical Case Scenario of Emerging Resistance Patterns to Dolutegravir: Implications for Treatment Strategies in Low- and Middle-Income Countries | C Chenwi
63 Pan-resistant HIV-1 in adults and adolescents with viraemia on dolutegravir-based ART in Africa | C Chimbetete
64 Pre-treatment HIV Drug Resistance Among Treatment-Naïve Infants and Children Newly Diagnosed with HIV in Papua New Guinea: Results from Clinic-Based Surveillance | A Kelly-Hanku
2023 WORKSHOP INFORMATION
Final programme – click here to download a copy
Presentations:
Wednesday, 20 September 2023
Advances in HIV treatment strategies | Monica Gandhi
Long acting injectable ART and PrEP – is it a gamechanger or more problems? | Jean Nachega
Introduction to HIV reservoirs | Monique Nijhuis
Characterization of the intact and defective HIV-1 reservoir at initiation and during 96 weeks of ART in people living with HIV-1 subtype C in South Africa | Lucas Hermans
Diagnostic uncertainty in people on PrEP | Gillian Hunt
The use of cabotegravir as long-acting PrEP will have a limited impact on drug resistance in men-who-have-sex-with-men in Thailand: A modelling study | David van de Vijver
Implications for ART from PrEP related resistance | Urvi Parikh
Assessment of the In Vitro Phenotypic Drug Susceptibility of HIV-1 Subtype C Drug Resistant Variants to Islatravir | Hyeonah Byun
In Vitro Phenotypic Doravirine Susceptibility of Prevalent HIV-1 Subtype C NNRTI-Resistance Mutations | Nikita Reddy
The use of atazanavir limits cross resistance to darunavir in the South African Public Sector | Hendrik Coetser
Patterns of INSTI-Associated DRMs in INSTI-Naïve PLWH Treated with DTG-Containing ART Regimens | Robert Shafer
Phenotypic Impact of INSTI-Associated DRMs Selected by DTG | Robert Shafer
Modelling the impact and cost effectiveness of resistance testing for pre-treatment, first-, second- and third-line failures | David van de Vijver
Close monitoring of dolutegravir resistance in patients with laboratory confirmed dolutegravir exposure: observations from a national HIV drug resistance survey in South Africa | Kim Steegen
Rapid Point-of-Care Dolutegravir Exposure Testing as a Reliable Tool for Assessing HIV Therapy Adherence | Chijioke Umunnakwe
Thursday, 21 September 2023
Paediatric HIVDR Cases from Eswatini | Sarah Perry
Three Case Reports of Dolutegravir Resistance in Pregnant and Breastfeeding Women in South Africa: Implications for Prevention of Vertical Transmission and Implementation of South Africa’s 2023 Antiretroviral Guidelines | Natasha Davies
Viral reservoir landscape of children with HIV in Botswana treated with dual bNAbs | Daniel Kuritzkes
Low Levels of Clinically Significant Drug Resistance Mutations to Dolutegravir amongst Children Living with HIV aged 0-15 years Failing on First-line ART in Uganda | Stephanie Hackett
Virological response and HIV drug resistance mutations among children in Yaounde-Cameroon: Evidence from a successful transition to pediatric dolutegravir-based regimens | Joseph Fokam
An Initiative to support Global Research in HIV Drug Resistance from the Division of AIDS | Keith Crawford
Impact Of Low-Frequency HIV-1 Drug Resistance Mutations On Antiretroviral Therapy Outcomes | Shuntai Zhou
In vitro studies on the mechanism of dolutegravir resistance caused by mutations in the HIV-1 3’-polypurine tract | Jeroen Van Kampen
Genotypic and Phenotypic Dolutegravir Resistance in Pregnant Women and Children Living with HIV-1 | Lisa Frenkel
Impact of Russian invasion in Ukraine on HIV-1 migration from phylodynamic perspective | Karol Serwin
Alternative mechanisms of drug resistance beyond the target genes | Roger Paredes
Friday, 22 September 2023
Cyclic Acquired HIV Drug Resistance to Dolutegravir among People living with HIV in Uganda. National Remnant Samples Surveillance 2022 | Grace Namayanja
Dolutegravir resistance detected during routine HIVDR testing of ART treatment-experienced patients in Johannesburg, South Africa | Lucia Hans
HIV Drug Resistance to Dolutegravir is Uncommon Among Adults Investigated for Treatment Failure in Malawi | Newton Kalata
2nd line therapy. What to do with people who are not suppressed | Cissy Kityo
Assessing Prevalence and Geographic Distribution of Antiretroviral Resistance in KwaZulu-Natal, South Africa: Implications for Dolutegravir-Based HIV Management | Steven Kemp
HIV Drug Resistance in the Dolutegravir Era: Preliminary Results from East Africa | Ajay Parikh
Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort study | Kwabena Asare
Dolutegravir resistance: multi-cohort analysis and mathematical modelling | Tom Loosli
Predicting the Impact of Long-Acting Cabotegravir and Rilpivirine as Treatment and Retention in Care on Antiretroviral Resistance: the CAB/RPV-LA MARISA Model | Nuri Han
2023 Botswana HIV Integrated Clinical Care Guidelines | Ava Avalos
Considerations for the future use of doravirine | Bronwyn Bosch
Prevalence of protease inhibitor resistance in patients with low-level viremia in the public sector in South Africa | Lucinda Gaelejwe
Can HIV Low Level Viremia Predict Future HIV treatment failure? A Retrospective Cohort Analysis From Zambia | Mwanza Wa Mwanza
Posters
Initiating HIV Therapy after cabotegravir pre-exposure prophylaxis exposure: A literature review and clinical trial protocol | Mark Siedner
Viral Non-suppression and HIV Drug Resistance among People who Inject Drugs and their Partners in Kenya | Bhavna Chohan
That new onset of symptomatic altered mental status in an ART experienced patient taking boosted Atazanavir based regimen could be CSF viral escape | Joseph Lutaakome
A Case Series of Three HIV-Infected Adults With Emerging Darunavir Drug Resistance Associated Mutations While Receiving First Generation Protease Inhibitors in Tanzania | Joan Rugemalila
THE INFLUENCE OF ANTIRETROVIRAL DRUGS AND HIV RESISTANCE MUTATIONS ON THE SHEDDING OF HIV-1 INTO PERITONEAL DIALYSIS EFFLUENT | Teboho Mooko
Interest and Performances of HIV Whole Genome Next‐Generation Sequencing in a diagnosis laboratory | Julia Dina
Policy and Program Practices for HIV Drug Resistance in PEPFAR-supported Countries, February 2020 | Kayla Sulzman
Surveillance and Laboratory Practices for HIV Drug Resistance in PEPFAR-Supported Countries, February 2020 | Kayla Sulzman
EVOLUTION of HIV-1 RESISTANCE and DRUG CONCENTRATIONS IN A WELL MONITORED COHORT IN SOUTH AFRICA | Yashna Singh
Evaluation Of an Enhanced Commercial Assay HIV Drug Resistance Assay Using Three External Quality Assessment Panels | Obiageli Okafor
Validation of A New Multiplex HIV-1 Genotyping Kit That Includes Integrase for High Throughput HIV Drug Resistance Testing in Low- and Middle-Income Countries | Cheri van der Walt
INNOVATIVE AND AFFORDABLE HIV-1 DRUG RESISTANCE TESTING FOR RESOURCE LIMITED SETTINGS | Sontaga Manyana
Evolution of HIV-1 envelope and Genotypic Broadly Neutralizing Antibody Susceptibility in Early Treated HIV-infected Infants | Kayla Delaney
Pharmaco-virological outcome and HIV genotypic resistance profiles among ARV-treated adolescents transitioning to a DTG-based regimen in Togo | Charlotte Charpentier
Stories of Success: Eswatini’s Decentralized National Pediatric HIV Drug Resistance Program | Sarah Perry
HIV-1 Resistance to Dolutegravir in a vertically-acquired HIV Patient in Tanzania | Reginald Gervas
Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV Resistance to Dolutegravir | Nuttada Panpradist
Viraemia and HIV Drug Resistance among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy | Richard Lessells
Transitioning to dolutegravir in a programmatic setting: Virological outcomes and associated factors among treatment-naïve patients with HIV-1 in the Kilombero and Ulanga antiretroviral cohort in rural Tanzania | Robert Ndege
Surveillance Drug Resistance Mutations to Dolutegravir among People Living with HIV-1 Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe | Vinie Kouamou
High viral suppression and detection of integrase inhibitor-resistance associated mutations in treatment-experienced adults living with HIV-1 in Dar es Salaam three years following the introduction of dolutegravir-based regimen in Tanzania | George Bwire
Limited treatment options as a result of HIV-1 mutations, ART related myositis and stockout medication, a case study | Mireille A Mpalang Kakubu
View past conference programmes:
- 2017 Workshop (click here to view)
- 2018 Workshop (click here to view)
- 2019 Workshop (click here to view)
- 2021 Workshop (click here to view)
Past conference information:
2021 WORKSHOP INFORMATION
Final programme – click here to download a copy
Presentations:
Monday, 6 September 2021
- Update on the continuing spread of HIV drug resistance | Gillian Hunt
- HIV Resistance Patterns in a Cohort of Adults Living with HIV Failing First-line Efavirenz-based Antiretroviral Therapy in South Africa | Bronwyn Bosch
- Resistance testing for management of HIV virologic failure in sub-Saharan Africa: An open randomized controlled trial | Mark Siedner
Monday, 13 September 2021
- HIV resistance to new antiretrovirals | Daniel Kuritzkes
- Global Perspectives on HIV Drug Resistance: The Division of AIDS (DAIDS) Strategy | Keith Crawford
- Evaluating Pre-existing Drug Resistance Mutations as a Contributor of HIV-1 Therapy Failure Following First or Second Exposure To Antiviral Therapy in Pregnant Women in Malawi | Shuntai Zhou
- Mutations in the HIV 3’polypurine tract can confer dolutegravir resistance | José Dekker
- Impact of Minority Drug Resistance Mutations on Risk of Virologic Failure in South Africa | Jonathan Li
- HIV Drug Resistance Minority Variants Partially Explain Genotypic-Phenotypic Discordance | Rami Kantor
- Dolutegravir Resistance in Non-Subtype B HIV-1 in PLHIV: Genotyping and Phenotyping Strategies and Results | Ceejay Boyce
- Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria | Nicaise Ndembi
Monday, 20 September 2021
- Rilpivirine cross-resistance could adversely affect long-acting cabotegravir-rilpivirine use in low and middle income settings | Kim Steegen
- Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants | Robert Smith
- HIV-1 Multi-class Drug Resistance in a Treatment Experienced Patient with Persistent Low-level Viraemia | Aabida Khan
Monday, 27 September 2021
- Preventing HIV Drug Resistance in children and adolescents | Mo Archary
- High Levels of Pretreatment HIV Drug Resistance among Treatment Naïve Infants Newly Diagnosed with HIV in 2016 in Namibia: Results of a Nationally Representative Survey | Michael Jordan
- PrEP & HIV Drug Resistance: More Complex and More Important! | John Mellors
- Use of Undetectable Equals Untransmittable (U=U) Messaging As A Strategy To Prevent transmission of resistance | Mandisa Dukashe
2019 WORKSHOP INFORMATION:
Final programme – click here to download a copy
Presentations:
Wednesday, 16 October 2019
- Viral escape | Monique Nijhuis
- Transmission of resistance | Michael Jordan
- Goals of programmatic treatment | Elliot Raizes
- HIV suppression: How well are we doing | Lucas Hermans
- What should be done to optimise viral suppression | Michelle Moorhouse
- Benefits and Pitfalls of resistance testing | Carole Wallis
- Mutations: Now you see them, now you don’t | Gert van Zyl
- Comparison of HIV-1 Viral Load and Drug Resistance Mutations between Cerebrospinal Fluid and Plasma in Patients with HIV and Cryptococcal Meningitis Co-infection in Botswana | Nametso Kelentse
- When Plasma Viral Load Does Not Answer the Question: ‘Is the Patient Failing Therapy?’ | Margaret Pascoe
- HIV cure research | Douglas Richman
- Understanding potential mechanism of cure by stem cell transplantation | Annemarie Wensing
Thursday, 17 October 2019
- Setting the scene | Francois Venter
- Drug level testing as a strategy to determine eligibility for drug resistance testing in HIV-infected patients with failure on second-line ART | Lucas Hermans
- Specific Guanosines in the HIV Leader RNA Direct Viral Genome Packaging | Chijioke Umunnakwe
- A Simple Alternative for HIV Drug Resistance Genotyping: Laboratory Evaluation of the PANDAA qDx HIVDR RTI assay | Lara Noble
- Simultaneous HIV-1 Quantification and Mutation Detection Using a Closed-Tube Assay | Robert Shafer
- High level of HIV re-suppression following Intensive Adherence Counselling for adults on Protease Inhibitor- based second- line antiretroviral therapy at an urban HIV clinic in Kampala, Uganda | Nakibuuka Violet
- Peripartum Virological Suppression and its Significant Implications for Elimination of Mother-To-Child Transmission of HIV in Resource-Constrained Settings of Eastern Cape, South Africa: Population Based Cohort Study | Oladele Adeniyi
- HIV-1 Drug Resistance Surveillance among Parturient Women on Anti-retroviral Therapy in the Eastern Cape, South Africa: Implications for Elimination of Mother-To-Child Transmission | Oladele Adeniyi
- HIV drug-resistance in children: Data demands use of different drugs | Lisa Frenkel
- HIV Drug Resistance in Samples from the Routine Early Infant Diagnosis Programme | Iqra Barakzai
- Resistance is common in paediatric patients failing ART in South Africa | Gillian Hunt
- Drug Resistance Evolution Using Sanger and NGS in Kenyan Youth Living with HIV | Vlad Novitsky
- The Presence of Archived HIV-1 Drug Resistance Mutations is Consistent with Advanced Clinical Stage and CD4-Nadir in Vertically-Infected Adolescents Failing Treatment | Joseph Fokam
- The role of NNRTIs in the treatment of children | Louise Kuhn
- The role of raltegravir | Leon Levin
- Debate: The role of raltegravir | Lee Fairlie
Friday, 18 October 2019
- Long-acting ARV formulations | Charles Flexner
- Islatravir (MK-8591): A Versatile NRTTI for HIV treatment and prevention | Jay Grobler
- GS-6207: long acting HIV capsid inhibitor | Martin Rhee
- Long-acting antibodies for treatment | Daniel Kuritzkes
- HIV Pseudo viremia from large defective cell population | Johannes Botha
- Acquired antiretroviral drug resistance associated with low level viremia in South African patients on antiretroviral therapy | Adriaan Basson
- Magnitude of Viral Load Does Not Correlate with Presence or Absence of HIV Drug Resistance at the Time of Virologic Failure on First-Line Antiretroviral Therapy in Sub-Saharan Africa | Suzanne McCluskey
- Pretreatment HIV Drug Resistance in Cuba Patients During the Period 2009-2017: Results of the National Survey | Liuber Yans Machado Zaldivar
- Complex clinical cases in the management of virologic failure and HIV drug resistance | Mark Siedner
- South African 3rd Line Antiretroviral Database – 2019 Update | Ruth Lancaster
- Third-Line Antiretroviral Therapy (ART) Program at Cecilia Makiwane Hospital, Eastern Cape, South Africa: Resistance Patterns and Temporal Data on Virological Suppression: 2019 Second Quarter Update | Dominique Kabengele Kayembe
2018 WORKSHOP INFORMATION:
Final programme – click here
Presentations:
Monday, 22 October 2018
- Will resistance ruin the rollout? | John Mellors
- Pretreatment HIV drug resistance in women in low- and middle- income countries | Seth Inzaule
- Pretreatment drug resistance is associated with virological failure in South African
patients on first-line ART – findings from the ITREMA trial | Lucas Hermans - Population-based Monitoring of HIV Drug Resistance Emerging in HIV-Positive Individuals during Antiretroviral Treatment and Related Programme Factors in Sentinel ART Sites in Malawi | George Bello
- HIV drug resistance in adults failing protease inhibitor (PI)-based antiretroviral therapy (ART) in KwaZulu-Natal | Melendhran Pillay
- Teratogenicity in relation to Dolutegravir | Ushma Mehta
- The Dolutegravir Dilemma: South African perspective | Francois Venter
- Mechanism of emergence of resistance of T97A during dolutegravir therapy | Kristi Huik
- Clinical Cases: Integrase Strand-Transfer Inhibitor Resistance | Julia Turner
- Untreatable HIV Infection In Zimbabwe | Cleophas Chimbetete
- Paediatric HIV Drug Resistance | Moherndran Archary
- HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe | Vinie Kouamou
Tuesday, 23 October 2018:
- Potential Clinical Role of Long- and Longer-Acting ART | Daniel Kuritzkes
- Pretreatment drug resistance and new treatment paradigms in first-line ART | Michelle Moorhouse
- Comparison of HIV Drug-Resistant Mutant Detection by NGS with and without Unique Molecular Identifiers | Kevin McCormick
- Amino Acid Prevalence of Mutations Detectable by Direct PCR versus Single Genome Sequencing | Robert Shafer
- Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping | Neil Parkin
- Characterization and data assessment of NGS-based genotyping using VQA HIVDR proficiency panels | Hezhao Ji
- PhyloPi: an affordable, purpose built phylogenetic pipeline for the HIV drug resistance testing facility | Phillip Bester
- Bioinformatic data processing pipelines in support of next generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus | Hezhao Ji
- Cerebrospinal Fluid (CSF) HIV Viral Escape (CVE): Clinical Resolution and CSF Viral Suppression Following Switching to a Genotype-guided South African Antiretroviral Third Line Regimen (TLR) with Good CSF Penetration | Dominique Kabengele Kayembe
- Persistent low-level viraemia on third-line ART | Richard Lessells
- Genotypic Resistance Testing in Routine Care in South Africa: Is the Juice Worth the Squeeze? | Mark Siedner
- Routine 1st-line resistance testing in the current treatment era: now is not the time | Emily Hyle
- Plenary: Achieving the last 90 | Elliot Raizes
Wednesday, 24 October 2018:
- Basics to understand HIV drug resistance | Carole Wallis
- How do we measure HIV drug resistance | Monique Nijhuis
- Impact of ART resistance in sub Saharan Africa | Elliot Raizes
- Barriers to adherence: predictors and markers of treatment response | John de Wit
- Understanding virological failure | Annemarie Wensing
- Integrated adherence counselling using biomedical and socio-economic information | Lucas Hermans
- Therapy success and failure: first, second and third line therapy | Francois Venter
- DTG Global roll out | Ava Avalos
- Future trends of drug resistance and prospects of antiviral therapy | Douglas Richman
2017 WORKSHOP INFORMATION:
Final programme – click here
Presentations:
Monday, 6 November 2017
- Why should drug resistance be prevented in clinical practice | Deenan Pillay
- HIV replication and selection of resistance: basic principles | Douglas Richman
- Assessment of resistance | Gillian Hunt
- Selection of resistance in clinical practice | Carole Wallis
- Clinical management of drug resistance | Annemarie Wensing
Tuesday, 7 November 2017
- Setting the scene: Overview of the resistance problem globally, reinforcing the need for the workshop | Yunus Moosa
- Pre-treatment HIV drug resistance in LMIC | Ravindra Gupta
- New technologies for drug resistance testing | Roger Paredes
- HIV DNA Genotyping by UDS compared with cumulative HIV RNA Genotypes in Pre-treated Patients | Ali Si-Mohammed
- PASeq.org: One-click, Cloud-based Web Service for NGS-based HIV genotyping Data Analysis | Marc Noguera-Julian
- HIV Drug Resistance in children and adolescents: Impact on treatment and outcomes | Lee Fairlie
- HIV-1 viral infectivity and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study | Jenny Coetzee
- A Public Sector Antiretroviral Treatment Programme for Treatment-Experienced Children and Adolescents in the Western Cape Province of South Africa Using Darunavir/Ritonavir-, Raltegravir- and Etravirine-Containing Regimens | James Nuttall
Wednesday, 8 November 2017
- HIV drug resistance and tracing outcomes among antiretroviral therapy defaulters in Malawi | Michael Jordan
- Variation in Genotypic Resistance Patterns in HIV-1 Non-B Subtypes in Uganda and South Africa | Suzanne McCluskey
- Whole Genome Deep Sequencing of HIV Reveals Extensive Multi-class Resistance in Nigerian Patients Failing First-line Antiretroviral Therapy | Kate El Bouzidi
- An Algorithm to Determine Appropriate Third-line Antiretroviral Regimens in Patients Failing Protease Inhibitor-based Regimens in Resource-limited Settings | Michelle Moorhouse
- HIV-1 drug resistance and third-line therapy outcomes in patients failing secondline therapy in Zimbabwe | Cleophas Chimbetete
- HIV Multi-Drug Resistance is still a Clinical Relevant Issue Despite its Dramatic Drop over the Years | Daniele Armenia
- ARVs old and new – where do they fit | Daniel Kuritzkes
- Emergence of High Level Resistance to Dolutegravir with T97A Mutation in Integrase in Treatment Experienced Patients with Baseline Partial Sensitivity to Dolutegravir | Jomy George
- Case Report: Detection of Multi-Drug Resistant HIV-1 in a Patient on Integrase Inhibitor Based Antiretroviral Therapy in Botswana | Kaelo Seatla
- Primary Resistance to Integrase Strand Transfer Inhibitors in Patients Infected with Diverse HIV-1 Subtypes in Sub-Saharan Africa | Seth Inzaule
- A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V and/or M184I (GS-US-292-1824) | Ignacio Perez-Valero
- Resistance Profile of HIV-1 Maturation Inhibitor GSK3532795 | Ira Dicker
- Trends of the Ongoing Spread of HIV Subtype A in Tel Aviv, Israel | Dan Turner
- Characterization of Subtype F HIV-1 Strains from Patients with Initial Poorer Treatment Response Compared to Individuals Infected with Subtype B HIV-1 Strains | Samira Joussef
- Trends of HIV-1 Drug Resistance During the Past 20 years of ARV Treatment in Uganda | Immaculate Nankya
Posters
- Time to Consider Dolutegravir for Treatment in Uganda: HIV-1 Drug Resistance Profiles of Virologic Failures on First-, Second, or Third-line/Raltegravir-containing Combined Antiretroviral Treatments | E Ndashimye
- Resistance Profile of HIV-1 Maturation Inhibitor GSK3532795 | I Dicker
- Developments in HIV policy from 2007 to 2017; Notification of HIV Resistance | G Levin
- Next Generation Sequencing of Pooled Samples and Comparison with Sanger Sequencing for the Detection of HIV Protease Inhibitor Mutations | M Yousif
- Neuro-Symptomatic Cerebrospinal Fluid/Plasma HIV RNA Levels Discordance With Possible Asynchronous And Discordant Emergence Of Drug Resistant HIV Variants | D Kabengele Kayembe
- Treatment outcomes and patterns of drug resistance in adolescents initiated on first-line antiretroviral treatment in Pretoria, South Africa | C Wallis
- HIV-1 viral infectivity and drug resistance amongst female sex workers in Soweto, South Africa: A cross sectional study | J Coetzee
- An Algorithm to Determine Appropriate Third-line Antiretroviral Regimens in Patients Failing Protease Inhibitor-based Regimens in Resource-limited Settings | M Moorhouse